Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Cabaletta Bio Appoints Experienced Financial Executive, Richard Henriques, to its Board of Directors
RADNOR, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
-
Mr. Marda joins Cabaletta with 17 years of financial leadership experience RADNOR, Pa., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and...
-
RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
-
RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio Inc., a biotechnology company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases, today...
-
Dr. Binder is an expert in T cell product development, translational research and GMP manufacturing Joins Cabaletta Bio as Executive Vice President, Science & Technology on February 1, 2019 ...
-
-- Carl June, M.D., who led discovery and development of the breakthrough CAR T platform at the University of Pennsylvania -- Jay Siegel, M.D., former head of Office of Therapeutics Research and...
-
-- Signs exclusive license agreement and multi-year sponsored research agreements with University of Pennsylvania -- Completes $38 million Series A financing to advance lead asset, DSG3-CAART for...